PI3K Inhibitors: Overall Survival, Adverse Events And Dose Optimization Top US FDA’s Concerns

 
• By Sue Sutter

Agency will ask its Oncologic Drugs Advisory Committee whether future approvals in the class should be supported by randomized data, instead of single-arm studies, given potential overall survival detriment seen in randomized trials to date for four drugs.

Repeating pattern
There is a concerning, repeating pattern in overall survival results from PI3K randomized, controlled trials, the FDA says. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers